HK Stock MarketDetailed Quotes

SIMCERE PHARMA (02096)

Watchlist
  • 13.690
  • -0.040-0.29%
Not Open Apr 14 16:08 CST
35.54BMarket Cap23.89P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

SIMCERE PHARMA (02096) Revenue Breakdown Overview

By Business/Source

Currency:CNY
2025/FY
Stock NameRevenueRatio
其他药品业务5.74B74.29%
抗肿瘤领域业务1.99B25.71%

By Product

Currency:CNY
2025/FY
Stock NameRevenueRatio
其他药品业务5.74B74.29%
抗肿瘤领域业务1.99B25.71%

By Country/Region

Currency:CNY
2025/H1
Stock NameRevenueRatio
China3.58B100.00%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +2.73%
Sample Name
Sample Code
 -5.80%
Sample Name
Sample Code
 -7.23%
4
CNOOC
00883
-8.59%
5
SHANGHAI PECHEM
00338
-12.24%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +36.57%
Sample Name
Sample Code
 +18.83%
Sample Name
Sample Code
 +14.83%
4
Ucloud Technology Co., Ltd
688158
+8.59%
5
Hangzhou Shunwang Technology
300113
+7.41%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -